Makers of a revolutionary cancer treatment asked to slash its 'eye-watering' cost
Daily Mail -

Nice today announced it was unable to approve a type of CAR-T therapy, called Yescarta, for thousands of non-Hodgkin lymphoma patients on the health service because it is so expensive.

Loading...

Related Articles